{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.5","value":"19"},{"groupId":"OG001","spread":"2.6","value":"15.5"},{"groupId":"OG002","spread":"3.2","value":"18"},{"groupId":"OG003","spread":"4.3","value":"16.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"18"}],"units":"Participants"}],"description":"Time to absolute neutrophil count (ANC) of \\> 1,000/uL on the first of three consecutive test results","dispersionType":"Standard Deviation","groups":[{"description":"HIGH-INTENSITY MYELOABLATIVE CONDITIONING: Patients undergo total body irradiation BID on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.\n\nTRANSPLANT: In all arms, patients undergo allogeneic HSCT with GCSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.\n\nGVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days with taper in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.","id":"OG000","title":"Arm A (MRD / High Intensity Conditioning)"},{"description":"LOWER-INTENSITY MYELOABLATIVE CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on day -6, fludarabine phosphate IV over 30 minutes on days -6 to -2, and thiotepa IV over 4 hours on days -5 and -4. Patients also undergo total body irradiation QD on days -2 and -1.\n\nTRANSPLANT: In all arms, patients undergo allogeneic HSCT with GCSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.\n\nGVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days and mycophenolate mofetil IV and PO every 8 hours on day -3 to approximately day 30, with or without taper at the discretion of the treating physician. Mycophenolate mofetil should be continued or resumed after day 30 if donor chimerism is low, after discussion with the Principal Investigator.","id":"OG001","title":"Arm B (MRD / Low Intensity Conditioning)"},{"description":"HIGH-INTENSITY MYELOABLATIVE CONDITIONING: Patients undergo total body irradiation BID on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.\n\nTRANSPLANT: In all arms, patients undergo allogeneic HSCT with G-CSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.\n\nGVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days with taper in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.","id":"OG002","title":"Arm C (MUD / High Intensity Conditioning)"},{"description":"LOWER-INTENSITY MYELOABLATIVE CONDITIONING: Patients receive cyclophosphamide IV over 1 hour on day -6, fludarabine phosphate IV over 30 minutes on days -6 to -2, and thiotepa IV over 4 hours on days -5 and -4. Patients also undergo total body irradiation QD on days -2 and -1.\n\nTRANSPLANT: In all arms, patients undergo allogeneic HSCT with G-CSF-mobilized CD34-enriched PBSC and CD45RA-depleted cells on day 0.\n\nGVHD PROPHYLAXIS: Beginning day -1, patients receive tacrolimus IV over 22-24 hours or PO (BID if given PO) for 50 days and mycophenolate mofetil IV and PO every 8 hours on day -3 to approximately day 30, with or without taper at the discretion of the treating physician. Mycophenolate mofetil should be continued or resumed after day 30 if donor chimerism is low, after discussion with the Principal Investigator.","id":"OG003","title":"Arm D (MUD / Low Intensity Conditioning)"}],"paramType":"MEDIAN","populationDescription":"Participants who received NTCD PBSC transplant and were alive at day 28 post-transplant","reportingStatus":"POSTED","timeFrame":"through Day 100 post-transplant","title":"Engraftment - ANC <1,000/uL","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Days"}